Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Clin Pharmacol Ther. 2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29.

    Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

    Source

    Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.

    Abstract

    Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.

    PMID:
    22378157
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3374459
    Free PMC Article

    Images from this publication.See all images (1)Free text

    Figure 1

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk